A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors Rosen, L., LoRusso, P., Ma, W., Goldman, J., Weise, A., Colevas, A., Adjei, A., Yazji, S., Shen, A., Johnston, S., Gates, M. R., Jones, C., Musib, L., De Crespigny, A., Chan, I., Sikic, B. AMER ASSOC CANCER RESEARCH. 2011

View details for DOI 10.1158/1538-7445.AM2011-4716

View details for Web of Science ID 000209701404368